Desktop Health™ Introduces the PrintRoll™ Rotating Build Platform for the 3D-Bioplotter® — a First-of-its-kind Bioprinting Tool to Develop Tubular Solutions for Vascular, Digestive, Respiratory, and Other Channels
24.7.2023 15:30:00 EEST | Business Wire | Press release
Desktop Health — the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. (NYSE: DM) — today announced a breakthrough in bioprinting with the launch of PrintRoll™, an innovative rotating build platform that can produce intelligent tubular solutions for the body’s vascular, digestive, respiratory, and reproductive channels on the 3D-Bioplotter premier bioprinting system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724680554/en/
Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health, examines two tubular medical devices printed on the new 3D-Bioplotter® PrintRoll™ rotating build platform in medical-grade materials. PrintRoll is designed to enable new medical solutions for the body’s thousands of miles of internal channels, such as vascular, digestive, and other systems. (Photo: Business Wire)
The 3D-Bioplotter is a highly sophisticated extrusion-based 3D printer that processes liquids, melts, pastes, gels, or other materials, including cells, through a needle tip on a Swiss-made, 3-axis gantry system with high accuracy and temperature, sterility, and design controls. 3D-Bioplotter offers eight printheads with the widest range of temperatures in bioprinting — from 2°C to 500°C (35.6°F to 932°F) — enabling complex, multi-material medical parts.
The PrintRoll add-on feature has been in development since 2019 as part of a collaboration with Johannes Gutenberg University Mainz, a public research university in Mainz, Germany.
“We are proud to offer the first bioprinting tool specifically designed to develop medical solutions for the thousands of miles of channels found in the human body,” said Ric Fulop, Founder and CEO of Desktop Metal. “Desktop Health exists to deliver 3D printing solutions that improve patient lives, and we are confident that PrintRoll, offered exclusively on the 3D-Bioplotter, will enable all-new regenerative innovations. We look forward to seeing what our customers will create next with this exciting new tool.”
Visit TeamDM.com/3DBioplotterBrochure to see a video of the PrintRoll in action and download the latest 3D-Bioplotter brochure, which chronicles 20+ years of innovations on the bioprinter by regenerative medicine experts.
How PrintRoll Works
The PrintRoll platform attaches to the modular build plate of the 3D-Bioplotter and features a motor-driven rotating mandrel with spring-loaded, easily exchangeable drums of different sizes. Rotating speed is tightly controlled by the 3D-Bioplotter’s easy-to-use software.
As the PrintRoll tool rotates, the printhead moves back and forth depositing material on the surface in the desired design. For example, polycaprolactone (PCL), a medical-grade, biodegradable plastic used in many FDA-cleared implants and devices, hardens quickly on the drum after the melted material is printed. In bioprinting, users typically produce a structure or scaffold in a stiff or flexible biocompatible material that is designed to repair and integrate with cells of the body, sometimes degrading after a certain period of time.
The PrintRoll comes with a 10 mm diameter drum – with 20 mm and 40 mm sizes available – designed to accommodate the development of solutions for a variety of human channels, which vary based on age and gender. Standard diameter sizes generally correspond to the diameters of the femoral artery (~10 mm), trachea (~10-20 mm), fallopian tube (~5-15 mm), aorta (~25 mm) esophagus (~30 mm), and a range of intestine segments (~40-100 mm).
The PrintRoll system supports printing hollow cylindrical structures up to 140 mm in length, depending on the printhead used. Custom sizes may also be available.
“Up until now, the creation of thin-walled cylindrical devices with complex structured walls has been challenging to accomplish with regenerative materials, such as hydrogels,” said Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health. “With the PrintRoll, materials are patterned directly on top of a substrate that rolls as the printhead also moves, supporting the deposited layers and therefore expanding the palette of materials that can be 3D printed into these important structures. Following printing, devices can be removed from the PrintRoll, leaving high-resolution and reproducible parts that customers have come to expect from the 3D-Bioplotter.”
The PrintRoll comes with a library of honeycomb designs and standard printing parameters for common materials. The PrintRoll platform, which is compatible with 4th Generation 3D-Bioplotter models, is available for pre-order now, with shipping expected in the fourth quarter. Contact Desktop Health to learn more at TeamDM.com/3DBioplotterMoreInfo .
3D-Bioplotter® Continues Pioneering Bioprinting
PrintRoll continues the long history of bioprinting innovations on the world’s most researched bioprinting system, as detailed in the last 3D-Bioplotter brochure.
This tradition is also continued with CMFlex™ — the first 3D printed regenerative bone graft substitute product cleared by the FDA and the first such clearance based on manufacturing on the 3D-Bioplotter. Developed by Dimension Inx, CMFlex is an easy-to-use flexible bone graft product that is 3D printed on a standard 3D-Bioplotter Manufacturer model. This new product is an alternative to an autograft, in which a physician intrusively harvests bone from one area of a patient’s body to repair damaged or diseased bone elsewhere in the body.
“The recent FDA clearance of CMFlex by Dimension Inx is a breakthrough for the field of additive, regenerative medicine – one that clearly showcases the robustness of the 3D-Bioplotter,” said Lou Azzarra, President of Desktop Health. “Commercial milestones like this often take many years, and we congratulate the entire team at Dimension Inx on this achievement.”
Visit TeamDM.com/3DBioplotterBrochure to download our latest brochure, which details how Dimension Inx developed CMFlex for commercialization.
About Desktop Metal
Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
_______________________
1“Hence, 3D Bioplotter® which was capable of cell-laden bioprinting, could be defined as the first commercial 3D bioprinter in the world.” Gu Z, Fu J, Lin H, He Y. Development of 3D bioprinting: From printing methods to biomedical applications. Asian J Pharm Sci. 2020 Sep;15(5):529-557. doi: 10.1016/j.ajps.2019.11.003. Epub 2019 Dec 17. PMID: 33193859; PMCID: PMC7610207. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610207/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724680554/en/
Contact information
Media Relations:
Sarah Webster
sarahwebster@desktopmetal.com
(313) 715-6988
Investor Relations:
Jay Gentzkow
jaygentzkow@desktopmetal.com
(781) 730-2110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a
Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
